ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1486

Cardiovascular Risk in Systemic Lupus Erythematosus: Carotid Ultrasonography Is Useful for the Re-stratification of Cardiovascular Risk Determined by Score2

Cristina Corrales Selaya1, Carmen Bejerano2, Carmen Secada Gómez3, Virginia Portilla-González4, Ricardo Blanco-Alonso5, Victor Manuel Martinez Taboada6, Leyre Riancho7 and alfonso Corrales-Martínez8, 1Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, 2Hospital Universitario Marques de Valdecilla, Immunopathology group, IDIVAL, Santander, Cantabria, Spain, 3Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 5Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, 6Facultad de Medicina. Universidad de Cantabria, Santander, Cantabria, Spain, 7Hospital Sierrallana, Torrelavega, Cantabria, Spain, 8Hospital Universitario Marques de Valdecilla, Santander, Spain

Meeting: ACR Convergence 2024

Keywords: Cardiovascular, Systemic lupus erythematosus (SLE), Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) patients have an increased cardiovascular (CV) risk compared to the general population. Although SCORE2 (systematic coronary risk evaluation 2) has improved the CV risk determination of the SCORE, it is still far from being well established in SLE. For this purpose, the research of tools that may identify high-risk SLE patients who may benefit from active therapy to prevent CV events is of major importance. The main objective is to determine if the use of carotid ultrasound may improve the stratification of CV risk determined by the SCORE2 in SLE patients.

Methods: Cross-sectional study of 161 SLE patients in which CV risk was initially categorized according to the SCORE2. Secondly, all of them underwent a carotid ultrasound for measurement of carotid intima-media thickness (C-IMT) and detection of carotid plaques. The presence of carotid plaque directly includes patients in the very high cardiovascular risk category.

Results: We included a total of 161 SLE patients of whom 27 were excluded from the final analysis because of very high CV risk (17 due to previous CV event, 6 Diabetes Mellitus (DM) and 4 chronic kidney disease (CKD).

The main characteristics of the remaining 134 patients included are shown in Table 1. Ninety-three percent of the patients were women with a mean age of 51 ± 13 years and disease duration of 12 ± 9 years. From the 134 patients, 43% (57) had carotid plaques.

Using SCORE2, patients were classified into 3 CV risk groups, low-moderate risk (111 cases, 83%), high risk (22, 16%) and very high risk (1, 1%). Table 2 shows the results of the carotid ultrasound study in relation to the CV risk groups classified by SCORE2. According to C-IMT, only 3.6% (4/111) of patients with low-moderate risk with SCORE2 and 13.6% (3/22) of patients with high risk were reclassified as very high CV risk (C-IMT > 0.9 mm). However, carotid plaque detection reclassified 36% (40/111) of patients with low-moderate risk by SCORE2 and 72.7% (16/22) of patients with high CV risk as very high CV risk.

In addition, all patients with C-IMT > 0.9 mm were found to have carotid plaque.

Conclusion: The presence of carotid plaque reclassifies to very high CV risk a significant number of SLE patients with low-moderate CV risk by SCORE2. The C-IMT study does not add any value to the carotid plaque study in the stratification of CV risk.

Supporting image 1

Table1. Main baseline characteristics of 134 SLE patients without previous CV Events, without DM and without CKD.

Supporting image 2

Table 2. SCORE2 risk in 134 patients with SLE, without previous CV events, without DM according to the C-IMT > 0.9 mm and carotid plaques.

Disclosures: C. Corrales Selaya: None; C. Bejerano: None; C. Secada Gómez: None; V. Portilla-González: None; R. Blanco-Alonso: AbbVie, 2, 5, 6, Bristol-Myers Squibb, 2, 6, Galapagos, 6, Janssen, 2, 6, Lilly, 2, 6, MSD, 2, 5, 6, Pfizer, 2, 6, Roche, 2, 5, 6; V. Martinez Taboada: None; L. Riancho: None; a. Corrales-Martínez: None.

To cite this abstract in AMA style:

Corrales Selaya C, Bejerano C, Secada Gómez C, Portilla-González V, Blanco-Alonso R, Martinez Taboada V, Riancho L, Corrales-Martínez a. Cardiovascular Risk in Systemic Lupus Erythematosus: Carotid Ultrasonography Is Useful for the Re-stratification of Cardiovascular Risk Determined by Score2 [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/cardiovascular-risk-in-systemic-lupus-erythematosus-carotid-ultrasonography-is-useful-for-the-re-stratification-of-cardiovascular-risk-determined-by-score2/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-risk-in-systemic-lupus-erythematosus-carotid-ultrasonography-is-useful-for-the-re-stratification-of-cardiovascular-risk-determined-by-score2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology